One‐year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients
Open Access
- 22 January 2007
- journal article
- Published by Wiley in Journal of Internal Medicine
- Vol. 261 (3) , 268-275
- https://doi.org/10.1111/j.1365-2796.2006.01762.x
Abstract
Objective. To determine whether adherence to clinic visits early after initiation of highly active antiretroviral therapy (HAART) is predictive of long-term clinical outcome. Design. Observational cohort study. Setting. A tertiary referral hospital. Subjects. A total of 387 adult HIV patients who were followed for at least 1 year after initiation of HAART between January 1998 and December 2004. Main outcome measurements. The effect of 1-year adherence to clinic visits on the occurrence of new AIDS-defining illness or death was assessed using Kaplan–Meier survival estimates, and hazard ratios were estimated using Cox proportional hazards regression model. Results. Multivariate analysis revealed that advanced clinical stage, fewer new drugs in HAART, and longer total elapsed time without clinical visits for 1 year after HAART were all significant risk factors for the occurrence of new AIDS-defining illnesses or death. Compared with no missed visits, the hazard ratio adjusted by clinical stage and number of new drugs in HAART was 2.87 (95% confidence interval [CI], 1.34–6.16, P = 0.007) for one missed appointment, 4.37 (95% CI: 1.74–10.98, P = 0.002) for two, and 8.19 (95% CI: 2.95–22.78, P < 0.001) for three or more. Conclusion. Adherence to clinic visits early after initiation of HAART is an independent predictor for long-term clinical progression in HIV patients.Keywords
This publication has 20 references indexed in Scilit:
- CD4 Lymphocyte Percentage Predicts Disease Progression in HIV‐Infected Patients Initiating Highly Active Antiretroviral Therapy with CD4 Lymphocyte Counts >350 Lymphocytes/mm3The Journal of Infectious Diseases, 2005
- Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and deathInternational Journal of STD & AIDS, 2004
- Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study GroupThe Journal of Infectious Diseases, 2004
- Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 × 109 cells/LAnnals of Internal Medicine, 2003
- Highly active antiretroviral therapy outcomes in a primary care clinicAIDS Care, 2003
- Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort studyThe Lancet, 1999
- Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection DurationJAMA, 1998
- Compliance/adherence and care management in HIV diseaseJournal of the Association of Nurses in AIDS Care, 1997
- Physicians' Experience with the Acquired Immunodeficiency Syndrome as a Factor in Patients' SurvivalNew England Journal of Medicine, 1996
- An overview of interventions to improve compliance with appointment keeping for medical servicesPublished by American Medical Association (AMA) ,1992